AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06782022
Drug: 5-Fluoro-Uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached.
Trial: NCT03714828
Drug: Injection of TVEC into target lesions - week 1-2
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient.
Trial: NCT03869892
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
Trial: NCT03714828
Drug: Injection of TVEC into target lesions 3wks after 1st injection
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses.
Trial: NCT03714828
Drug: Injection of TVEC into target lesions 2wks after 2nd injection
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Trial: NCT03714828
Drug: Injection of TVEC into target lesions 2wks after 3rd injection
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses.
Trial: NCT02616666
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
Trial: NCT01998841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the schedule specified in the treatment arm.
Trial: NCT02586155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic RVX000222 100 mg capsule
Trial: NCT02586155
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-Intensity Statin
Trial: NCT00141778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once a day
Trial: NCT00141778
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally, once a day
Trial: NCT03093701
Drug: TLC399 (ProDex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-vial system: TLC399-DSP and TLC399-Lipid
Trial: NCT02258763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
Trial: NCT03682172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hour intravenous infusion with saline water
Trial: NCT00902044
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes
Trial: NCT04683250
Drug: TAS0953/HM06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
Trial: NCT04683250
Drug: TAS0953/HM06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
Trial: NCT04005066
Drug: Elunate®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
Trial: NCT02891668
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
Trial: NCT02636569
Drug: topical diclofenac daily
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed.
Trial: NCT02636569
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
Trial: NCT01746849
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02970500
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00709969
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
Trial: NCT00931372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT00379613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
Trial: NCT00642512
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03889743
Drug: placebo treatment during 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Trial: NCT00169169
Drug: ACVBP
RxNorm normalized name: ACVBP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00169169
Drug: ACE
RxNorm normalized name: Acet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02210364
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 150 mg tablets
Trial: NCT00302796
Drug: Bioclavid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 + 125 mg times 3 or 6
Trial: NCT00302796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03621605
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by slow IV infusion or SC injection.
Trial: NCT01505296
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propafenone, flecainide, sotalol, dofetilide
Trial: NCT03302338
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: distilled water 20 ml/kg/day for maximum of 7 days.
Trial: NCT01421563
Drug: Anplag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Trial: NCT00508066
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, 4ml/hour for 72 hours.
Trial: NCT04227015
Drug: CTA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTA101 UCAR-T cell injection by intravenous infusion
Trial: NCT04000282
Drug: SAR442085
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
Trial: NCT04474002
Drug: 4L Klean Prep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
Trial: NCT04474002
Drug: 1L Klean prep® and 2 sachets Picoprep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
Trial: NCT00275197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01154920
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
Trial: NCT01849237
Drug: Standard therapy of septic shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Trial: NCT04768699
Drug: TQG203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Trial: NCT03681249
Drug: ShenqiDihuang Decoction placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
Trial: NCT04768699
Drug: TQG203/NovoSeven®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
Trial: NCT04768699
Drug: TQG203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Trial: NCT02019160
Drug: 25% AgNO3 solution followed by 5% NaF varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of 4.4μg±1.4μg fluoride per use
Trial: NCT02019160
Drug: 38% SDF solution followed by placebo varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of 8.8μg±2.8μg fluoride per use
Trial: NCT00454051
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
Trial: NCT01628029
Drug: Therapeutic Melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02614716
Drug: LY3090106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02614716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02242864
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242864
Drug: MicardisPlus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01350245
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
Trial: NCT00866359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)
Trial: NCT02500576
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04639284
Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
Trial: NCT01433055
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
Trial: NCT01433055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
Trial: NCT02717455
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.
Trial: NCT02115490
Drug: Bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00733005
Drug: Matching placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Trial: NCT04552353
Drug: Vaway
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Trial: NCT01564537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib placebo-matching capsules
Trial: NCT00880178
Drug: Simvastatin and Extended-Release niacin
RxNorm normalized name: niacin / simvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Trial: NCT00880178
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Trial: NCT00591773
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Trial: NCT00591773
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Trial: NCT00591773
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Trial: NCT00825760
Drug: Topical placebo gel plus light
FDA approved: no
EMA approved: no
PMDA approved: no